Mulsun Biotech key facts
as of Oct 2026- Developer and provider of industrialized silkworm rearing systems and silk protein-based products designed for year-round, high-efficiency, and sustainable production.
- Mulsun Biotech is valued at approximately $511.5M as of Oct 2026 (last reported valuation).
- It has raised $77.7M; the latest was IPO in Jan 2026.
- Notable investors include Fosun Venture Capital Investment, China Merchants Group, Central SOEs Industrial Investment Fund for Poor Area, Gaoyun Capital, Hangzhou Shengchuang Jiye Private Equity Fund Management — 7 tracked in total.
- Status: Privately Held (backing).
Mulsun Biotech's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·Watch Mulsun Biotech: the Monday email on marks, rounds and moves
Mulsun Biotech funding rounds
No funding rounds for Mulsun Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Mulsun Biotech valuation
Mulsun Biotech's last reported valuation was $512 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
Mulsun Biotech investors
7 investors are on record for Mulsun Biotech, including Fosun Venture Capital Investment, China Merchants Group, Central SOEs Industrial Investment Fund for Poor Area and Gaoyun Capital.
About Mulsun Biotech
Developer and provider of industrialized silkworm rearing systems and silk protein-based products designed for year-round, high-efficiency, and sustainable production. The company enables textile, cosmetic, food, and packaging industries with stable, high-quality biomaterials through its integrated, technology-driven platform.
- Sector
- Materials and Resources
- HQ
- Shaoxing, China
- Founded
- 2015
- Employees
- 1,098
- Website
- lxm3s.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.